Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer
Background Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two‐year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Methods Retrospective review of the two‐year local control (LC), local‐regional control (LRC) within the same lobe, OS,...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2020-08, Vol.42 (8), p.1939-1953 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1953 |
|---|---|
| container_issue | 8 |
| container_start_page | 1939 |
| container_title | Head & neck |
| container_volume | 42 |
| creator | Pasalic, Dario Betancourt‐Cuellar, Sonia L. Taku, Nicolette Ludmir, Ethan B. Lu, Yi Allen, Pamela K. Tang, Chad Antonoff, Mara B. Fuller, Clifton D. Rosenthal, David I. Morrison, William H. Phan, Jack Garden, Adam S. Welsh, James W. Chang, Joe Y. Liao, Zhongxing Erasmus, Jeremy J. Nguyen, Quynh‐Nhu |
| description | Background
Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two‐year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy.
Methods
Retrospective review of the two‐year local control (LC), local‐regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018.
Results
Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow‐up was 20 months (range: 9.0‐97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14‐0.64; P = .008). OS in oligometastatic non‐SCC and SCC were 100% and 66% (P = .03). There were no grade ≥3 toxicities.
Conclusions
Metastatic pulmonary HNCs after SABR have a two‐year OS rate comparable to pulmonary metastasectomy. |
| doi_str_mv | 10.1002/hed.26117 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2424645403</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2424645403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-42d31bf8d8cc3bcf3947f4142a2042f8dfef3b4b46862aeb40c9d58892ce0b853</originalsourceid><addsrcrecordid>eNp1kM9O3DAQh60KVLa0h74AssSJQxb_mU2cY7Vsu0hIXOAcOc6ka0ji1HZY9hn60njZ5Yg0ksejT9-MfoT85GzOGRPXG2zmIue8-EJmnJVFxiQUJ_seZCZZAWfkWwhPjDGZg_hKzqTgolyAmpH_91M0rsdA9dDQ6F6tsdGmb-u6zm3t8JeGiB5d1CZaQ3Xd6WhfkHrdWBc36PW4S7Cn49T1btB-R3uMOqRKFjvQMfE4xEC3Nm7o6G2_Zzaom_eVA5pnavRg0H8np63uAv44vufk8ffqYbnO7u7_3C5_3WVGKlVkIBrJ61Y1yhhZm1aWULTAQWjBQKR5i62soYZc5UJjDcyUzUKpUhhktVrIc3J58I7e_ZswxOrJTX5IKysBAnJYAJOJujpQxrsQPLbV8faKs2ofe5Vir95jT-zF0TjVfZp-kB85J-D6AGxth7vPTdV6dXNQvgGT9I95</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424645403</pqid></control><display><type>article</type><title>Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Pasalic, Dario ; Betancourt‐Cuellar, Sonia L. ; Taku, Nicolette ; Ludmir, Ethan B. ; Lu, Yi ; Allen, Pamela K. ; Tang, Chad ; Antonoff, Mara B. ; Fuller, Clifton D. ; Rosenthal, David I. ; Morrison, William H. ; Phan, Jack ; Garden, Adam S. ; Welsh, James W. ; Chang, Joe Y. ; Liao, Zhongxing ; Erasmus, Jeremy J. ; Nguyen, Quynh‐Nhu</creator><creatorcontrib>Pasalic, Dario ; Betancourt‐Cuellar, Sonia L. ; Taku, Nicolette ; Ludmir, Ethan B. ; Lu, Yi ; Allen, Pamela K. ; Tang, Chad ; Antonoff, Mara B. ; Fuller, Clifton D. ; Rosenthal, David I. ; Morrison, William H. ; Phan, Jack ; Garden, Adam S. ; Welsh, James W. ; Chang, Joe Y. ; Liao, Zhongxing ; Erasmus, Jeremy J. ; Nguyen, Quynh‐Nhu</creatorcontrib><description>Background
Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two‐year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy.
Methods
Retrospective review of the two‐year local control (LC), local‐regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018.
Results
Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow‐up was 20 months (range: 9.0‐97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14‐0.64; P = .008). OS in oligometastatic non‐SCC and SCC were 100% and 66% (P = .03). There were no grade ≥3 toxicities.
Conclusions
Metastatic pulmonary HNCs after SABR have a two‐year OS rate comparable to pulmonary metastasectomy.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.26117</identifier><identifier>PMID: 32129548</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Head & neck cancer ; Lung cancer ; Metastases ; Metastasis ; Neck ; oligometastasis ; pulmonary metastases ; pulmonary oligometastases ; Radiation therapy ; Squamous cell carcinoma ; stereotactic body radiotherapy ; Toxicity</subject><ispartof>Head & neck, 2020-08, Vol.42 (8), p.1939-1953</ispartof><rights>2020 Wiley Periodicals, Inc.</rights><rights>2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-42d31bf8d8cc3bcf3947f4142a2042f8dfef3b4b46862aeb40c9d58892ce0b853</citedby><cites>FETCH-LOGICAL-c3887-42d31bf8d8cc3bcf3947f4142a2042f8dfef3b4b46862aeb40c9d58892ce0b853</cites><orcidid>0000-0003-4511-8291 ; 0000-0002-5472-5344 ; 0000-0002-5264-3994</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.26117$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.26117$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32129548$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pasalic, Dario</creatorcontrib><creatorcontrib>Betancourt‐Cuellar, Sonia L.</creatorcontrib><creatorcontrib>Taku, Nicolette</creatorcontrib><creatorcontrib>Ludmir, Ethan B.</creatorcontrib><creatorcontrib>Lu, Yi</creatorcontrib><creatorcontrib>Allen, Pamela K.</creatorcontrib><creatorcontrib>Tang, Chad</creatorcontrib><creatorcontrib>Antonoff, Mara B.</creatorcontrib><creatorcontrib>Fuller, Clifton D.</creatorcontrib><creatorcontrib>Rosenthal, David I.</creatorcontrib><creatorcontrib>Morrison, William H.</creatorcontrib><creatorcontrib>Phan, Jack</creatorcontrib><creatorcontrib>Garden, Adam S.</creatorcontrib><creatorcontrib>Welsh, James W.</creatorcontrib><creatorcontrib>Chang, Joe Y.</creatorcontrib><creatorcontrib>Liao, Zhongxing</creatorcontrib><creatorcontrib>Erasmus, Jeremy J.</creatorcontrib><creatorcontrib>Nguyen, Quynh‐Nhu</creatorcontrib><title>Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two‐year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy.
Methods
Retrospective review of the two‐year local control (LC), local‐regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018.
Results
Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow‐up was 20 months (range: 9.0‐97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14‐0.64; P = .008). OS in oligometastatic non‐SCC and SCC were 100% and 66% (P = .03). There were no grade ≥3 toxicities.
Conclusions
Metastatic pulmonary HNCs after SABR have a two‐year OS rate comparable to pulmonary metastasectomy.</description><subject>Head & neck cancer</subject><subject>Lung cancer</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neck</subject><subject>oligometastasis</subject><subject>pulmonary metastases</subject><subject>pulmonary oligometastases</subject><subject>Radiation therapy</subject><subject>Squamous cell carcinoma</subject><subject>stereotactic body radiotherapy</subject><subject>Toxicity</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kM9O3DAQh60KVLa0h74AssSJQxb_mU2cY7Vsu0hIXOAcOc6ka0ji1HZY9hn60njZ5Yg0ksejT9-MfoT85GzOGRPXG2zmIue8-EJmnJVFxiQUJ_seZCZZAWfkWwhPjDGZg_hKzqTgolyAmpH_91M0rsdA9dDQ6F6tsdGmb-u6zm3t8JeGiB5d1CZaQ3Xd6WhfkHrdWBc36PW4S7Cn49T1btB-R3uMOqRKFjvQMfE4xEC3Nm7o6G2_Zzaom_eVA5pnavRg0H8np63uAv44vufk8ffqYbnO7u7_3C5_3WVGKlVkIBrJ61Y1yhhZm1aWULTAQWjBQKR5i62soYZc5UJjDcyUzUKpUhhktVrIc3J58I7e_ZswxOrJTX5IKysBAnJYAJOJujpQxrsQPLbV8faKs2ofe5Vir95jT-zF0TjVfZp-kB85J-D6AGxth7vPTdV6dXNQvgGT9I95</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Pasalic, Dario</creator><creator>Betancourt‐Cuellar, Sonia L.</creator><creator>Taku, Nicolette</creator><creator>Ludmir, Ethan B.</creator><creator>Lu, Yi</creator><creator>Allen, Pamela K.</creator><creator>Tang, Chad</creator><creator>Antonoff, Mara B.</creator><creator>Fuller, Clifton D.</creator><creator>Rosenthal, David I.</creator><creator>Morrison, William H.</creator><creator>Phan, Jack</creator><creator>Garden, Adam S.</creator><creator>Welsh, James W.</creator><creator>Chang, Joe Y.</creator><creator>Liao, Zhongxing</creator><creator>Erasmus, Jeremy J.</creator><creator>Nguyen, Quynh‐Nhu</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0003-4511-8291</orcidid><orcidid>https://orcid.org/0000-0002-5472-5344</orcidid><orcidid>https://orcid.org/0000-0002-5264-3994</orcidid></search><sort><creationdate>202008</creationdate><title>Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer</title><author>Pasalic, Dario ; Betancourt‐Cuellar, Sonia L. ; Taku, Nicolette ; Ludmir, Ethan B. ; Lu, Yi ; Allen, Pamela K. ; Tang, Chad ; Antonoff, Mara B. ; Fuller, Clifton D. ; Rosenthal, David I. ; Morrison, William H. ; Phan, Jack ; Garden, Adam S. ; Welsh, James W. ; Chang, Joe Y. ; Liao, Zhongxing ; Erasmus, Jeremy J. ; Nguyen, Quynh‐Nhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-42d31bf8d8cc3bcf3947f4142a2042f8dfef3b4b46862aeb40c9d58892ce0b853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Head & neck cancer</topic><topic>Lung cancer</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neck</topic><topic>oligometastasis</topic><topic>pulmonary metastases</topic><topic>pulmonary oligometastases</topic><topic>Radiation therapy</topic><topic>Squamous cell carcinoma</topic><topic>stereotactic body radiotherapy</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pasalic, Dario</creatorcontrib><creatorcontrib>Betancourt‐Cuellar, Sonia L.</creatorcontrib><creatorcontrib>Taku, Nicolette</creatorcontrib><creatorcontrib>Ludmir, Ethan B.</creatorcontrib><creatorcontrib>Lu, Yi</creatorcontrib><creatorcontrib>Allen, Pamela K.</creatorcontrib><creatorcontrib>Tang, Chad</creatorcontrib><creatorcontrib>Antonoff, Mara B.</creatorcontrib><creatorcontrib>Fuller, Clifton D.</creatorcontrib><creatorcontrib>Rosenthal, David I.</creatorcontrib><creatorcontrib>Morrison, William H.</creatorcontrib><creatorcontrib>Phan, Jack</creatorcontrib><creatorcontrib>Garden, Adam S.</creatorcontrib><creatorcontrib>Welsh, James W.</creatorcontrib><creatorcontrib>Chang, Joe Y.</creatorcontrib><creatorcontrib>Liao, Zhongxing</creatorcontrib><creatorcontrib>Erasmus, Jeremy J.</creatorcontrib><creatorcontrib>Nguyen, Quynh‐Nhu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pasalic, Dario</au><au>Betancourt‐Cuellar, Sonia L.</au><au>Taku, Nicolette</au><au>Ludmir, Ethan B.</au><au>Lu, Yi</au><au>Allen, Pamela K.</au><au>Tang, Chad</au><au>Antonoff, Mara B.</au><au>Fuller, Clifton D.</au><au>Rosenthal, David I.</au><au>Morrison, William H.</au><au>Phan, Jack</au><au>Garden, Adam S.</au><au>Welsh, James W.</au><au>Chang, Joe Y.</au><au>Liao, Zhongxing</au><au>Erasmus, Jeremy J.</au><au>Nguyen, Quynh‐Nhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2020-08</date><risdate>2020</risdate><volume>42</volume><issue>8</issue><spage>1939</spage><epage>1953</epage><pages>1939-1953</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two‐year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy.
Methods
Retrospective review of the two‐year local control (LC), local‐regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018.
Results
Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow‐up was 20 months (range: 9.0‐97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14‐0.64; P = .008). OS in oligometastatic non‐SCC and SCC were 100% and 66% (P = .03). There were no grade ≥3 toxicities.
Conclusions
Metastatic pulmonary HNCs after SABR have a two‐year OS rate comparable to pulmonary metastasectomy.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32129548</pmid><doi>10.1002/hed.26117</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-4511-8291</orcidid><orcidid>https://orcid.org/0000-0002-5472-5344</orcidid><orcidid>https://orcid.org/0000-0002-5264-3994</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2020-08, Vol.42 (8), p.1939-1953 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_journals_2424645403 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Head & neck cancer Lung cancer Metastases Metastasis Neck oligometastasis pulmonary metastases pulmonary oligometastases Radiation therapy Squamous cell carcinoma stereotactic body radiotherapy Toxicity |
| title | Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A57%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20and%20toxicities%20following%20stereotactic%20ablative%20radiotherapy%20for%20pulmonary%20metastases%20in%20patients%20with%20primary%20head%20and%20neck%20cancer&rft.jtitle=Head%20&%20neck&rft.au=Pasalic,%20Dario&rft.date=2020-08&rft.volume=42&rft.issue=8&rft.spage=1939&rft.epage=1953&rft.pages=1939-1953&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.26117&rft_dat=%3Cproquest_cross%3E2424645403%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424645403&rft_id=info:pmid/32129548&rfr_iscdi=true |